In focus · trending topic

galectin proteins

23 stories · following the connections

Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

By Nasdaq OMXMar 21, 2017, 12:30 PM UTC

GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)

By Nasdaq OMXMar 14, 2017, 12:47 PM UTC

Galectin Therapeutics to Present at 29th Annual ROTH Conference

By Nasdaq OMXMar 9, 2017, 1:30 PM UTC

Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis

By Nasdaq OMXMar 6, 2017, 1:31 PM UTC

Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis

By Nasdaq OMXMar 6, 2017, 1:31 PM UTC

Galectin Therapeutics to Present at BIO CEO & Investor Conference

By Nasdaq OMXFeb 8, 2017, 1:30 PM UTC

Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials

By Nasdaq OMXFeb 7, 2017, 9:40 PM UTC

Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial

By Nasdaq OMXFeb 1, 2017, 1:10 PM UTC